Search research articles
Contact Us
Filters
Showing results (11-20 of 61) with videos related to
Page
of 7
Sort By:
World Journal of Gastroenterology
|
July 31, 2025
Gut microbiome-specific nanoparticle-based therapeutics for liver diseases
Amit Khurana, Phillipp Hartmann
Pharmacological Reviews
|
June 24, 2025
Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease
Natalie Rodriguez, Phillipp Hartmann
Frontiers in Medicine
|
September 4, 2023
How to calculate sample size in animal and human studies
Xinlian Zhang, Phillipp Hartmann
World Journal of Hepatology
|
June 12, 2023
Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease
Dulshan Jayasekera, Phillipp Hartmann
Microbial Cell (Graz, Austria)
|
August 29, 2024
Fecal gelatinase does not predict mortality in patients with alcohol-associated hepatitis
Yongqiang Yang, Phillipp Hartmann, Bernd Schnabl
International Immunology
|
July 6, 2022
Liver cirrhosis and immune dysfunction
Elda Hasa, Phillipp Hartmann, Bernd Schnabl
Frontiers in Physiology
|
October 23, 2012
The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease
Phillipp Hartmann, Wei-Chung Chen, Bernd Schnabl
Pediatric Obesity
|
December 10, 2025
BMI Percentile Cutoffs for Overweight and Obesity Are Set Too High in Terms of Adiposity and Metabolic Markers for Asian Children and Adolescents
Suk-Jin Hong, Xinlian Zhang, Phillipp Hartmann
Alcoholism, Clinical and Experimental Research
|
April 16, 2015
Alcoholic liver disease: the gut microbiome and liver cross talk
Phillipp Hartmann, Caroline T Seebauer, Bernd Schnabl
JAMA Network Open
|
July 16, 2025
Prevalence of Extremely Severe Obesity and Metabolic Dysfunction Among US Children and Adolescents
Eliane Münte, Xinlian Zhang, Amit Khurana, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 61) with videos related to
Sort By:
Page
of 7
World Journal of Gastroenterology
|
July 31, 2025
Gut microbiome-specific nanoparticle-based therapeutics for liver diseases
Amit Khurana, Phillipp Hartmann
Pharmacological Reviews
|
June 24, 2025
Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease
Natalie Rodriguez, Phillipp Hartmann
Frontiers in Medicine
|
September 4, 2023
How to calculate sample size in animal and human studies
Xinlian Zhang, Phillipp Hartmann
World Journal of Hepatology
|
June 12, 2023
Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease
Dulshan Jayasekera, Phillipp Hartmann
Microbial Cell (Graz, Austria)
|
August 29, 2024
Fecal gelatinase does not predict mortality in patients with alcohol-associated hepatitis
Yongqiang Yang, Phillipp Hartmann, Bernd Schnabl
International Immunology
|
July 6, 2022
Liver cirrhosis and immune dysfunction
Elda Hasa, Phillipp Hartmann, Bernd Schnabl
Frontiers in Physiology
|
October 23, 2012
The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease
Phillipp Hartmann, Wei-Chung Chen, Bernd Schnabl
Pediatric Obesity
|
December 10, 2025
BMI Percentile Cutoffs for Overweight and Obesity Are Set Too High in Terms of Adiposity and Metabolic Markers for Asian Children and Adolescents
Suk-Jin Hong, Xinlian Zhang, Phillipp Hartmann
Alcoholism, Clinical and Experimental Research
|
April 16, 2015
Alcoholic liver disease: the gut microbiome and liver cross talk
Phillipp Hartmann, Caroline T Seebauer, Bernd Schnabl
JAMA Network Open
|
July 16, 2025
Prevalence of Extremely Severe Obesity and Metabolic Dysfunction Among US Children and Adolescents
Eliane Münte, Xinlian Zhang, Amit Khurana, et al.
Page
of 7